keywords: Antibiotics, biofilm, Klebsiella pneumoniae, resistance, susceptibility, uropathogens
Uropathogenic K. pneumoniae is one of the prominent uropathogens that plays a major rule in biofilm formation. Microbial biofilms pose a public health problem for the persons who require indwelling medical devices, as the microorganisms in the biofilms are difficult to treat with antimicrobial agents. This study determined the biofilm production and antibiotic susceptibility pattern of K. pneumoniae isolated from Ahmadu Bello University Teaching Hospital, Zaria. Isolates from urine samples submitted to the Medical Microbiology Laboratory of the hospital were collected and identified using standard microbiological techniques. The isolates were evaluated for their biofilm production potentials and their susceptibility to antibiotics was determined. From the 180 uropathogens isolated, 55 (37.93%) were K. pneumoniae. The result of biofilm production showed most of the K. pneumoniae to be biofilm producers (63.64%). The antibiotic susceptibility testing showed that, the isolates were generally resistant to amoxicillin (78.18%), chloramphenicol (69.09%), tetracycline (63.64), cotrimoxazole (60.00%), ceftriaxone (49.09), ceftazidime (47.30%), ciprofloxacin (47.27%) and gentamicin (40.00%) while being uniformly susceptible to meropenem (90.90%), amikacin (85.45%) and piperacillin-tazobactam (83.64). A total of 76% of the isolates had MAR indices ≥ 0.3 indicating the prior exposure of these uropathogens to these antibiotics and up to 74.55% of the K. pneumoniae were multidrug resistant. However, the difference between the multidrug resistance of the biofilm-positive and biofilm-negative K. pneumoniae isolates was not statistically significant (P< 0.05) in this study.
Abdallah MN, Elsayed SB, Mostafa YMM & El-gohary GM 2011. Biofilm forming bacteria isolated from urinary tract infection, relation to catheterization and susceptibility to antibiotics. Int. J. Biot. & Mol. Biol. Res., 2(10): 172 – 178. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM & Loh E 2005. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis., 1(41): 354 – 367. Bolaji RO, Onaolapo JA, Ibrahim YKE & Igwe JC 2013. Incidence of Uropathogens from Asymptomatic Bacteriuria Pregnant Women in Zaria. Nigeria. Nig. J. Pharm. Sci., 12(1): 1 – 8. Chakraborty P & Nishith KP 2008. Manual of Practical Microbiology and Parasitology. New central book agency limited, 8/1 Chintamoni Das Lane, Kolkata 700 009, West Bengal, India. Cheesbrough M 2006. Medical Laboratory Manual for Tropical Countries, II Micrbiology (ELBS), Butterworth, Kent, UK, pp. 23 – 78. Christensen GD, Simpson WA, Younger JJ, Baddour LM, Barrett FF & Melton DM 1985. Adherence of coagulase-negative Staphylococci to plastic tissue culture plates: a quantitative model for the adherence of Staphylococci to medical devices. J. Clin. Microbiol. 22: 996 1006. Daniyan SY & Ojo BA 2013. Prevalence and antimicrobial susceptibility of urinopathogen among patients in a tertiary Health Institution in Ado Ekiti, Nig..Int. J. Biom. & Adv. Res., 04(02): 112 – 117. Dohnt K, Sauer M, Müller M, Atallah K, Weidemann M, Gronemeyer P, Rasch D, Tielen P & Krull R 2011. An in vitro urinary tract catheter system toinvestigate biofilm development in catheter-associated urinary tract infections. J. Microbiol. Met., 87 (3): 302 308. Donlan RM 2001. Biofilms and device-associated infections. Emerg. Infect. Dis., 7: 277 – 281. El-Astal Z 2005. Bacterial pathogens and their antimicrobial susceptibility in Gaza Strip, Palestine. Pak. J. Med. Sci., 20(4): 365 - 370. EUCAST 2011. Breakpoint tables for interpretation of MICs and zone diameters. European Committee on Antimicrobial Susceptibility Testing; Version 1.3. Eyoh AB, Toukam M, Atashili J, Fokunang C, Gonsu H, Lyonga EE, Mandi H, Ikomey G, Mukwele B, Mesembe M & Assoumou MC 2014. Relationship between multiple drug resistance and biofilm formation in Staphylococcus aureus isolated from medical and non-medical personnel in Yaounde, Cameroon. Pan Afri. Med. J., 17: 186. Fitzpatrick F, Humphreys H & OGara JP 2005. The genetics of staphylococcal biofilm formation: will a greater understanding of pathogenesis lead to better management of device-related infection. Clin. Microbiol. & Infect. Dis., 11 (12): 967 – 973. Gilbert P, Das J & Foley I1997. Biofilms susceptibility to antimicrobials. Adv. Dent. Res., 11: 160 – 167. Getenet B & Wondewosen T 2011. Bacterial uropathogens in urinary tract infection & antibiotic susceptibility pattern in Jimma University specialized hospital, southwest Ethiopia. Ethio. J. H. Sci., 21: (2). Hryniewicz K, Szczypa K, Sulikowska A, Jankowski K, Betlejewska K & Hryniewicz W 2001. Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland. J. Antimicr. Chemo., 47: 773 – 780. Krumpermann PH1985. Multiple antibiotics resistance indexing of E. coli to identify high risks compared with controls. 713: 163 – 168. Laupland KB, Ross T, Pitout JD, Church DL & Gregson DB 2007. Investigation of sources of potential bias in laboratory surveillance for anti-microbial resistance. Clin. & Invest. Med., 30(4): 159 – 166. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB., Stelling J., Struelens MJ., Vatopoulos V, Weber JT & Monnet DL 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. & Infect., 18: 268 – 281. Maldonado NC, Ruiz SC, Cecilia M & Nader-Macias ME 2007. A simple technique to detect Klebsiella biofilm-forming-strains. Topics and Trends in Applied Microbiology A. Méndez-Vilas (Ed.). Formatex: 52-59. Merritt J. Daniel E. Kadouri & O’Toole GA 2005. Growing and Analyzing Static Biofilms Current Protocols in Microbiology 1B.1.1-1B.1.17. Nicolle LE 2005. Complicated urinary tract infection in adults. The Can. J. Infect. Dis. & Med. Microbiol., 16(6): 349 – 360. Olayinka AT, Onile BA & Olayinka BO 2004. Prevalence of Multi-Drug Resistant (MDR) Pseudomonas aeruginosaIsolates in Surgical Units of Ahmadu Bello University Teaching Hospital, Zaria, Nigeria: An Indication for Effective Control Measures. Ann. Afr. Med., 3(1): 13 16. Olufunmiso OO & Oluwaseun A 2011. In vitro susceptibility of some uropathogens & a comparative assessment of antibacterial activities of local and imported multidiscs. J. Bact. Res., 3(6): 101 – 107. Osazuwa F, Mordi RM, Osazuwa E,Taiwo SS Alli OAT, Ogbolu DO, Akanni EO & Anukam KC 2010. Klebsiella has taken lead among uropathogens in University of Benin Teaching Hospital, Benin City, Nigeria-An observation.N. Y. Sci. J., 12(1): 3. Patel R 2005. Biofilms and antimicrobial resistance. Clin. Orth. & Rel. Res., 437: 41 – 47. Potera C 2009. Antibiotic Resistance: Biofilm Dispersing Agent Rejuvenates Older Antibiotics. Env. H. Persp., 118(7): A 288. Ruiz J 2003. Mechanisms of resistance to quinolones: target alterations, decreased accumulation and DNA gyrase protection. J. Antimicr. Chem., 51: 1109 – 1117. Savas L, Guvel S, Onlen Y, Savas N & Duran N 2006. Nosocomial urinary tract infections: micro-organisms, antibiotic sensitivities and risk factors. W. Ind. Med. J., 55(3): 188 – 193. Shigemura K, Tanaka K, Okada H, Nakano Y, Kinoshita S, Gotoh A, Arakawa S & Fujisawa M 2005. Pathogen occurrence and antimicrobial susceptibility of urinary tract infection cases during a 20-year period (1983-2002) at a single institution in Japan. Jap. J. Infect. Dis., 58: 303 – 308. Shirtliff M & Leid J 2009. The Role of Biofilms in Device-Related Infections. Bacteriology Springer, New York, NY. Stahlhut S, Struve C, Krogfelt K & Reisner A 2012. Biofilm formation of Klebsiella pneumoniae on urethralcatheters requires either type 1 or type 3 fimbriae. FEMS Immuno. & Med. Microbiol., 65: 350 – 359. Varsha G 2007. An update on newer betalactamases. Ind. J. Med. Res., 126: 417 – 427. Watnick P & Kolter R 2000. Biofilm, city of microbes. J. bact., 182(10), 2675 – 2679. Zahar J, Lortholary O, Martin C, Potel G, Plesiat P & Nordmann P 2009. Addressing the challenge of ESBLs. Cur. Opin. Invest. Drugs, 10(2): 172 – 180.